Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Rapid mucosal CD4(+) T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaques.
- S. Kewenig, T. Schneider, +7 authors M. Zeitz
- Biology, Medicine
- Gastroenterology
- 1 May 1999
BACKGROUND & AIMS
Human immunodeficiency virus (HIV) infection leads to severe immunologic and functional disturbances in the intestinal tract in late stages of the disease. Information on mucosal… Expand
Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma.
BACKGROUND
Marginal zone lymphoma (MZL) is a non-Hodgkin lymphoma that occurs as extra nodal, nodal, or splenic. While MZL is generally considered an indolent disease, a substantial percentage of… Expand
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a…
- C. Buske, E. Hoster, +17 authors W. Hiddemann
- Medicine
- Leukemia
- 2009
Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy… Expand
HIV/SIV Enteropathy
- M. Zeitz, R. Ullrich, T. Schneider, S. Kewenig, K. Hohloch, E. O. Riecken
- Biology, Medicine
- Annals of the New York Academy of Sciences
- 1 November 1998
ABSTRACT: Evidence is increasing that HIV/SIV‐induced changes in the highly differentiated gut‐associated immune system play a central role in the pathogenesis of gastrointestinal manifestations in… Expand
Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
- C. Kollmannsberger, J. Beyer, +9 authors C. Bokemeyer
- Medicine
- Journal of clinical oncology : official journal…
- 2004
PURPOSE
Long-term survival is rarely achieved in patients with cisplatin-refractory germ cell cancer (GCT). Both single-agent gemcitabine and oxaliplatin have shown activity in patients who… Expand
Iron release from transferrin by pyoverdin and elastase from Pseudomonas aeruginosa.
- C. Wolz, K. Hohloch, +6 authors G. Doering
- Biology, Medicine
- Infection and immunity
- 1 September 1994
Pseudomonas aeruginosa produces the siderophores pyoverdin and pyochelin as well as receptors for siderophores in response to iron deprivation. Previously, it has been shown in vitro that at neutral… Expand
Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms.
- M. Tzvetkov, G. Behrens, V. P. O'Brien, K. Hohloch, J. Brockmöller, P. Benöhr
- Biology, Medicine
- Pharmacogenomics
- 19 October 2011
AIM
We investigated whether genetic polymorphisms may contribute to the interpatient variability of cisplatin-induced nephrotoxicity.
PATIENTS & METHODS
Polymorphisms in the candidate genes GSTM1,… Expand
Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan
- A. Kuehne, R. Kaiser, +8 authors J. Brockmöller
- Biology, Medicine
- Pharmacogenetics and genomics
- 1 July 2007
Objectives Melphalan is widely used in the treatment of multiple myeloma. Pharmacokinetics of this alkylating drug shows high inter-individual variability. As melphalan is a phenylalanine derivative,… Expand
Treatment of Early Stage Nodal Follicular Lymphoma Using Involved-Field Radiotherapy and Rituximab: Preliminary Results of the Mir Trial (phase II study of the German Low Grade Lymphoma Study Group…
- K. Herfarth, M. Engelhard, +7 authors M. Dreyling
- Medicine
- 16 November 2012
Abstract 1634 Background: The commonly recommended treatment for early stage follicular lymphoma grade 1 or grade 2 (stage I/II) is involved-field radiotherapy (IF RT). However, a prospective German… Expand
Radioimmunotherapy Confers Long-Term Survival to Lymphoma Patients with Acceptable Toxicity: Registry Analysis by the International Radioimmunotherapy Network
- K. Hohloch, A. Delaloye, +7 authors L. Trümper
- Medicine
- The Journal of Nuclear Medicine
- 1 September 2011
The Radioimmunotherapy Network (RIT-N) is a Web-based, international registry collecting long-term observational data about radioimmunotherapy-treated patients with malignant lymphoma outside… Expand